DK1401837T3 - Purinderivater som A2B-adenosinreceptorantagonister - Google Patents

Purinderivater som A2B-adenosinreceptorantagonister

Info

Publication number
DK1401837T3
DK1401837T3 DK02749704T DK02749704T DK1401837T3 DK 1401837 T3 DK1401837 T3 DK 1401837T3 DK 02749704 T DK02749704 T DK 02749704T DK 02749704 T DK02749704 T DK 02749704T DK 1401837 T3 DK1401837 T3 DK 1401837T3
Authority
DK
Denmark
Prior art keywords
optionally substituted
receptor antagonists
adenosine receptor
purine derivatives
sup
Prior art date
Application number
DK02749704T
Other languages
English (en)
Inventor
Jeff A Zablocki
Venkata Palle
Vaibhav Varkhedkar
Dengming Xiao
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1401837T3 publication Critical patent/DK1401837T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK02749704T 2001-06-29 2002-06-27 Purinderivater som A2B-adenosinreceptorantagonister DK1401837T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30220801P 2001-06-29 2001-06-29

Publications (1)

Publication Number Publication Date
DK1401837T3 true DK1401837T3 (da) 2005-11-07

Family

ID=23166757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02749704T DK1401837T3 (da) 2001-06-29 2002-06-27 Purinderivater som A2B-adenosinreceptorantagonister

Country Status (11)

Country Link
US (2) US6770651B2 (da)
EP (1) EP1401837B1 (da)
JP (1) JP4335000B2 (da)
KR (2) KR100883292B1 (da)
AT (1) ATE307132T1 (da)
CA (1) CA2451244C (da)
DE (1) DE60206756T2 (da)
DK (1) DK1401837T3 (da)
ES (1) ES2247356T3 (da)
HK (1) HK1064096A1 (da)
WO (1) WO2003002566A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
AU2002357295A1 (en) * 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
ES2311759T3 (es) * 2003-05-06 2009-02-16 Cv Therapeutics, Inc. Derivados de xantina como antagonistas del receptor a2b de adenosina.
NL1023355C2 (nl) * 2003-05-07 2004-11-09 Oce Tech Bv Hot melt inkt omvattend een mengsel van kleurstoffen.
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2005009445A1 (en) * 2003-07-22 2005-02-03 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
US8455489B2 (en) * 2003-11-10 2013-06-04 Exelixis, Inc. Substituted pyrimidine compositions and methods of use
US20080280926A1 (en) * 2003-12-16 2008-11-13 Palle Venkata P Phosphodiesterase Inhibitors
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
JP2009504803A (ja) 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
WO2007142755A2 (en) * 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
US7470697B2 (en) * 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
EP2200615A1 (en) * 2007-10-16 2010-06-30 Gilead Palo Alto, Inc. A3 adenosine receptor antagonists
CN102088974A (zh) * 2008-02-07 2011-06-08 加利福尼亚大学校务委员会 用tlr7活化剂对膀胱疾病的治疗
CA2718983C (en) 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
EP2306838A4 (en) * 2008-07-16 2011-12-14 King Pharmaceuticals Res & Dev METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
BRPI1008383A2 (pt) 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
CN102438624B (zh) 2009-03-13 2016-03-30 阿德维纳斯治疗私人有限公司 取代的稠合嘧啶化合物
ES2542555T3 (es) * 2009-03-20 2015-08-06 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivados oxidados de triazolilpurinas útiles como ligandos del receptor A2A de adenosina y su uso como medicamentos
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
CN103237548A (zh) 2010-06-30 2013-08-07 吉利德科学股份有限公司 A2b腺苷受体拮抗剂用于治疗肺高血压的应用
US8940751B2 (en) 2010-09-13 2015-01-27 Advinus Therapeutics Private Limited Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
US10414768B2 (en) * 2014-12-05 2019-09-17 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
TWI746545B (zh) * 2016-04-26 2021-11-21 日商大日本住友製藥股份有限公司 經取代嘌呤衍生物
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
PE20220166A1 (es) * 2019-03-05 2022-01-28 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
IL148366A0 (en) 1999-08-31 2002-09-12 Univ Vanderbilt Selective antagonists of a2b adenosine receptors
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
AU2002357295A1 (en) * 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists

Also Published As

Publication number Publication date
WO2003002566A1 (en) 2003-01-09
DE60206756D1 (de) 2006-03-02
HK1064096A1 (en) 2005-01-21
KR20040023634A (ko) 2004-03-18
EP1401837B1 (en) 2005-10-19
KR100897219B1 (ko) 2009-05-14
CA2451244C (en) 2012-01-17
KR100883292B1 (ko) 2009-02-11
CA2451244A1 (en) 2003-01-09
DE60206756T2 (de) 2006-07-13
US20040209899A1 (en) 2004-10-21
EP1401837A1 (en) 2004-03-31
ES2247356T3 (es) 2006-03-01
ATE307132T1 (de) 2005-11-15
US7238700B2 (en) 2007-07-03
US6770651B2 (en) 2004-08-03
JP4335000B2 (ja) 2009-09-30
US20030064999A1 (en) 2003-04-03
JP2004536102A (ja) 2004-12-02
KR20080081208A (ko) 2008-09-08

Similar Documents

Publication Publication Date Title
DK1401837T3 (da) Purinderivater som A2B-adenosinreceptorantagonister
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
CY1117132T1 (el) Παραγωγο θειαζολιου
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
MXPA04003795A (es) Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos.
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
NO20052496L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
EA200600333A1 (ru) Производные индазола
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
WO2004069133A3 (en) N-monoacylated o-phenylenediamines as anti -cancer agents
NO20033145L (no) Purinderivater som purinergiske reseptorantagonister
WO2006110884A8 (en) 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
WO2003022219A3 (en) Biarylamino purine antiproliferative agents
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
WO2003068776A1 (fr) Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
EA200400545A1 (ru) Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов